Byetta sales take a hit as Amylin sets sights on Bydureon approval, pledges financial discipline
This article was originally published in Scrip
As Amylin Pharmaceuticals works with the US FDA and the firm's partners Lilly and Alkermes to clear the final hurdles towards approval of their diabetes drug Bydureon, which was rejected for a second time this past October, the biotech intends to remain focused on managing its business and expenses "as carefully as we have over the past two years," said CEO Daniel Bradbury
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.